What is Vicapsys Life Sc's earnings per share (EPS)?

Vicapsys Life Sc (VICP) reported diluted earnings per share of $-0.03 for fiscal year 2023. This represents a 0.0% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Vicapsys Life Sc Financials

VICP

Source SEC Filings (10-K/10-Q) Updated Sep 30, 2024 Currency USD FYE December

This page shows Vicapsys Life Sc (VICP) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 5 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Financial Profile 13/100

Based on FY2023 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →

Health score ≠ stock price. This rates the quality of Vicapsys Life Sc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Leverage

Vicapsys Life Sc carries a low D/E ratio of -1.02, meaning only $-1.02 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 75/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

Vicapsys Life Sc's current ratio of 0.02 is below the typical benchmark, resulting in a score of 0/100. This tight liquidity could limit financial flexibility if cash inflows slow.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

N/A

EBITDA

N/A

Net Income

N/A

EPS (Diluted)

$-0.03

YoY+0.0%

Vicapsys Life Sc earned $-0.03 per diluted share (EPS) in fiscal year 2023. This represents an increase of 0.0% from the prior year.

Cash & Balance Sheet

Free Cash Flow

N/A

Cash & Debt

$9K

YoY-33.2%

Vicapsys Life Sc held $9K in cash against $0 in long-term debt as of fiscal year 2023.

Dividends Per Share

N/A

Shares Outstanding

32M

YoY+0.5%

Vicapsys Life Sc had 32M shares outstanding in fiscal year 2023. This represents an increase of 0.5% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

N/A

Capital Allocation

R&D Spending

$15K

YoY+16.6%

Vicapsys Life Sc invested $15K in research and development in fiscal year 2023. This represents an increase of 16.6% from the prior year.

Share Buybacks

N/A

Capital Expenditures

N/A

VICP Income Statement

Metric	FY23	FY22	FY21	FY20	FY19
Revenue	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$15K+16.6%	$13K-26.0%	$18K-82.7%	$102K+3.2%	$99K
SG&A Expenses	$96K+60.2%	$60K+68.2%	$36K-23.8%	$47K-13.2%	$54K
Operating Income	N/A	N/A	-$337K+56.0%	-$766K	N/A
Interest Expense	$5K	N/A	N/A	N/A	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A
Net Income	N/A	N/A	-$237K+69.1%	-$766K+45.7%	-$1.4M
EPS (Diluted)	$-0.030.0%	$-0.03	N/A	N/A	N/A

Metric	Q3'24	Q2'24	Q1'24	Q4'23	Q3'23	Q2'23	Q1'23	Q4'22
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$4K-62.5%	$10K+2807.0%	$344	N/A	$3K+63.3%	$2K-80.0%	$10K	N/A
SG&A Expenses	$4K+44.9%	$3K-91.9%	$35K	N/A	$27K+75.8%	$15K+306.9%	$4K	N/A
Operating Income	-$199K-9.4%	-$182K+11.0%	-$204K	N/A	-$175K-29.3%	-$136K+35.8%	-$211K	N/A
Interest Expense	$37K+344.2%	$8K+122.6%	-$37K	N/A	$10K	N/A	N/A	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$236K-23.9%	-$190K+41.9%	-$327K	N/A	-$240K-77.1%	-$136K+35.8%	-$211K	N/A
EPS (Diluted)	$-0.010.0%	$-0.010.0%	$-0.01	N/A	$-0.01	$0.00+100.0%	$-0.01	N/A

VICP Balance Sheet

Metric	FY23	FY22	FY21	FY20	FY19
Total Assets	$40K-44.9%	$72K-87.9%	$594K+47.1%	$404K-42.1%	$698K
Current Assets	$40K-44.9%	$72K-67.7%	$223K+17456.6%	$1K-99.5%	$264K
Cash & Equivalents	$9K-33.2%	$14K-93.5%	$217K+17023.3%	$1K-99.5%	$264K
Inventory	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$2.0M+92.4%	$1.0M+42.9%	$716K-16.1%	$853K+115.2%	$396K
Current Liabilities	$2.0M+92.4%	$1.0M+42.9%	$716K-16.1%	$853K+115.2%	$396K
Long-Term Debt	N/A	N/A	N/A	N/A	N/A
Total Equity	-$1.9M-102.9%	-$951K-681.6%	-$122K+72.9%	-$449K-248.7%	$302K
Retained Earnings	-$16.3M-7.8%	-$15.1M-7.0%	-$14.1M-1.7%	-$13.9M-5.8%	-$13.1M

Metric	Q3'24	Q2'24	Q1'24	Q4'23	Q3'23	Q2'23	Q1'23	Q4'22
Total Assets	$90K	N/A	N/A	$40K-81.0%	$208K-44.9%	$378K+497.5%	$63K-12.1%	$72K
Current Assets	$90K	N/A	N/A	$40K-81.0%	$208K-44.9%	$378K+497.5%	$63K-12.1%	$72K
Cash & Equivalents	$90K	N/A	N/A	$9K-82.4%	$54K-76.9%	$231K+5486.4%	$4K-70.6%	$14K
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$2.7M	N/A	N/A	$2.0M+27.6%	$1.5M+4.8%	$1.5M+22.2%	$1.2M+17.8%	$1.0M
Current Liabilities	$2.7M+11.8%	$2.4M+8.4%	$2.3M+14.6%	$2.0M+27.6%	$1.5M+4.8%	$1.5M+22.2%	$1.2M+17.8%	$1.0M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	-$2.6M-8.2%	-$2.4M-8.4%	-$2.3M-17.0%	-$1.9M-44.6%	-$1.3M-22.0%	-$1.1M+4.2%	-$1.1M-20.0%	-$951K
Retained Earnings	-$17.1M-1.4%	-$16.8M-1.1%	-$16.6M-2.0%	-$16.3M-3.8%	-$15.7M-1.6%	-$15.5M-0.9%	-$15.3M-1.4%	-$15.1M

VICP Cash Flow Statement

Metric	FY23	FY22	FY21	FY20	FY19
Operating Cash Flow	N/A	-$238K+46.3%	-$444K-68.9%	-$263K+72.9%	-$970K
Capital Expenditures	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	N/A	N/A	$100K	N/A	N/A
Financing Cash Flow	N/A	$35K-93.8%	$560K	N/A	$1.1M
Dividends Paid	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A

Metric	Q3'24	Q2'24	Q1'24	Q4'23	Q3'23	Q2'23	Q1'23	Q4'22
Operating Cash Flow	-$40K-755.7%	$6K+165.4%	-$9K+88.5%	-$82K+23.6%	-$107K+50.8%	-$218K-2090.4%	-$10K-444.8%	$3K
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Financing Cash Flow	$130K	N/A	N/A	$38K+153.9%	-$70K	N/A	N/A	-$15K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

VICP Financial Ratios

Metric	FY23	FY22	FY21	FY20	FY19
Gross Margin	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	N/A	N/A	N/A	-466.8%
Return on Assets	N/A	N/A	-39.9%+149.7pp	-189.5%+12.3pp	-201.8%
Current Ratio	0.02-0.1	0.07-0.2	0.31+0.3	0.00-0.7	0.67
Debt-to-Equity	-1.02+0.1	-1.08+4.8	-5.89-4.0	-1.90-3.2	1.31
FCF Margin	N/A	N/A	N/A	N/A	N/A

Metric	Q3'24	Q2'24	Q1'24	Q4'23	Q3'23	Q2'23	Q1'23	Q4'22
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	-262.9%	N/A	N/A	N/A	-115.3%-79.4pp	-35.9%+297.9pp	-333.8%	N/A
Current Ratio	0.03	N/A	N/A	0.02-0.1	0.14-0.1	0.26+0.2	0.05-0.0	0.07
Debt-to-Equity	-1.03	N/A	N/A	-1.02+0.1	-1.16+0.2	-1.35-0.3	-1.06+0.0	-1.08
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Note: Shareholder equity is negative (-$1.9M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.

Note: The current ratio is below 1.0 (0.02), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.

Similar Companies

Medicenna Therapeutics Corp MDNAF

$25.0M

Hemogenyx Pharma HOPHF

$15.8M

Nurexone Biologic Inc NRXBF

$35.6M

Helix Biopharma HBPCF

$130.6M

Arch Biopartners ACHFF

$24.5M

Frequently Asked Questions

What are Vicapsys Life Sc's total assets?

Vicapsys Life Sc (VICP) had $40K in total assets as of fiscal year 2023, including both current and long-term assets.

How much does Vicapsys Life Sc spend on research and development?

Vicapsys Life Sc (VICP) invested $15K in research and development during fiscal year 2023.

How many shares does Vicapsys Life Sc have outstanding?

Vicapsys Life Sc (VICP) had 32M shares outstanding as of fiscal year 2023.

What is Vicapsys Life Sc's current ratio?

Vicapsys Life Sc (VICP) had a current ratio of 0.02 as of fiscal year 2023, which is below 1.0, which may suggest potential liquidity concerns.

What is Vicapsys Life Sc's debt-to-equity ratio?

Vicapsys Life Sc (VICP) had a debt-to-equity ratio of -1.02 as of fiscal year 2023, measuring the company's financial leverage by comparing total debt to shareholder equity.

Why is Vicapsys Life Sc's debt-to-equity ratio negative or unusual?

Vicapsys Life Sc (VICP) has negative shareholder equity of -$1.9M as of fiscal year 2023, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.

How financially healthy is Vicapsys Life Sc?

Vicapsys Life Sc (VICP) scores 13 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.